» Authors » David N Rush

David N Rush

Explore the profile of David N Rush including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 814
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rampersad C, Wiebe C, Balshaw R, Bullard J, Cortes Villalobos A, Trachtenberg A, et al.
Transplant Direct . 2025 Jan; 10(3):e1579. PMID: 39877647
Background: Epstein-Barr virus (EBV) chronic high viral load (CHVL) may be defined by >16 000 copies/mL whole blood or >200 copies/10 peripheral blood mononuclear cells in >50% samples exceeding 6...
2.
Campbell P, Cantarovich M, Gangji A, Houde I, Jevnikar A, Monroy-Cuadros F, et al.
Clin Transplant . 2024 Dec; 39(1):e70067. PMID: 39739990
Introduction: Novel approaches to improve long-term outcomes in kidney transplant recipients are required. Here, we present the 5-year data from a multicenter, prospective, Phase 3b trial evaluating treatment outcomes with...
3.
Rampersad C, Wiebe C, Balshaw R, Bullard J, Gibson I, Trachtenberg A, et al.
Clin Transplant . 2024 May; 38(5):e15329. PMID: 38722085
Background: Immunosuppression reduction for BK polyoma virus (BKV) must be balanced against risk of adverse alloimmune outcomes. We sought to characterize risk of alloimmune events after BKV within context of...
4.
Wiebe C, Balshaw R, Gibson I, Ho J, Shaw J, Karpinski M, et al.
Am J Transplant . 2023 Aug; 23(12):1882-1892. PMID: 37543094
De novo donor-specific antibody (dnDSA) after renal transplantation has been shown to correlate with antibody-mediated rejection and allograft loss. However, the lack of proven interventions and the time and cost...
5.
Rampersad C, Balshaw R, Gibson I, Ho J, Shaw J, Karpinski M, et al.
Am J Transplant . 2021 Oct; 22(3):761-771. PMID: 34717048
The prevalence and long-term impact of T cell-mediated rejection (TCMR) is poorly defined in the modern era of tacrolimus/mycophenolate-based maintenance therapy. This observational study evaluated 775 kidney transplant recipients with...
6.
Nickerson P, Balshaw R, Wiebe C, Ho J, Gibson I, Bridges N, et al.
Am J Transplant . 2020 Sep; 21(4):1503-1512. PMID: 32956576
Improving long-term kidney transplant outcomes requires novel treatment strategies, including delayed calcineurin inhibitor (CNI) substitution, tested using informative trial designs. An alternative approach to the usual superiority-based trial is a...
7.
Wiebe C, Rush D, Gibson I, Pochinco D, Birk P, Goldberg A, et al.
Am J Transplant . 2020 Mar; 20(9):2499-2508. PMID: 32185878
Prognostic biomarkers of T cell-mediated rejection (TCMR) have not been adequately studied in the modern era. We evaluated 803 renal transplant recipients and correlated HLA-DR/DQ molecular mismatch alloimmune risk categories...
8.
Rampersad C, Shaw J, Gibson I, Wiebe C, Rush D, Nickerson P, et al.
Am J Kidney Dis . 2019 Sep; 75(1):138-143. PMID: 31515140
Improving precision in predicting alloreactivity is an important unmet need and may require individualized consideration of non-HLA antibodies. We report a 21-year-old man with kidney failure from immunoglobulin A nephropathy...
9.
Navarrete M, Wilkins J, Lao Y, Rush D, Nickerson P, Ho J
Transplantation . 2019 Apr; 103(9):1790-1798. PMID: 30985576
Enzyme activity may be more pathophysiologically relevant than enzyme quantity and is regulated by changes in conformational status that are undetectable by traditional proteomic approaches. Further, enzyme activity may provide...
10.
Ho J, Sharma A, Kroeker K, Carroll R, De Serres S, Gibson I, et al.
BMJ Open . 2019 Apr; 9(4):e024908. PMID: 30975673
Introduction: Subclinical inflammation is an important predictor of death-censored graft loss, and its treatment has been shown to improve graft outcomes. Urine CXCL10 outperforms standard post-transplant surveillance in observational studies,...